145 related articles for article (PubMed ID: 28439967)
1. Involvement of the heparanase procoagulant domain in bleeding and wound healing.
Crispel Y; Ghanem S; Attias J; Kogan I; Brenner B; Nadir Y
J Thromb Haemost; 2017 Jul; 15(7):1463-1472. PubMed ID: 28439967
[TBL] [Abstract][Full Text] [Related]
2. Novel peptides that inhibit heparanase activation of the coagulation system.
Axelman E; Henig I; Crispel Y; Attias J; Li JP; Brenner B; Vlodavsky I; Nadir Y
Thromb Haemost; 2014 Sep; 112(3):466-77. PubMed ID: 25030319
[TBL] [Abstract][Full Text] [Related]
3. Tissue factor-heparanase complex: intracellular nonhemostatic effects.
Ghanem S; Keren-Politansky A; Kaplan V; Crispel Y; Nadir Y
Res Pract Thromb Haemost; 2023 Aug; 7(6):102179. PubMed ID: 37767062
[TBL] [Abstract][Full Text] [Related]
4. Peptides inhibiting heparanase procoagulant activity significantly reduce tumour growth and vascularisation in a mouse model.
Crispel Y; Axelman E; Tatour M; Kogan I; Nevo N; Brenner B; Nadir Y
Thromb Haemost; 2016 Sep; 116(4):669-78. PubMed ID: 27535490
[TBL] [Abstract][Full Text] [Related]
5. Heparanase procoagulant activity in cancer progression.
Nadir Y; Brenner B
Thromb Res; 2016 Apr; 140 Suppl 1():S44-8. PubMed ID: 27067977
[TBL] [Abstract][Full Text] [Related]
6. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI).
Dockal M; Hartmann R; Fries M; Thomassen MC; Heinzmann A; Ehrlich H; Rosing J; Osterkamp F; Polakowski T; Reineke U; Griessner A; Brandstetter H; Scheiflinger F
J Biol Chem; 2014 Jan; 289(3):1732-41. PubMed ID: 24275667
[TBL] [Abstract][Full Text] [Related]
7. Heparanase procoagulant activity as a predictor of wound necrosis following diabetic foot amputation.
Peled E; Melamed E; Portal TB; Axelman E; Norman D; Brenner B; Nadir Y
Thromb Res; 2016 Mar; 139():148-53. PubMed ID: 26916313
[TBL] [Abstract][Full Text] [Related]
8. An assay to evaluate heparanase procoagulant activity.
Nadir Y; Kenig Y; Drugan A; Shafat I; Brenner B
Thromb Res; 2011 Oct; 128(4):e3-8. PubMed ID: 21481923
[TBL] [Abstract][Full Text] [Related]
9. Heparanase in the Coagulation System.
Nadir Y
Adv Exp Med Biol; 2020; 1221():771-784. PubMed ID: 32274737
[TBL] [Abstract][Full Text] [Related]
10. Suppressive Role of Tissue Factor Pathway Inhibitor-α in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength.
Thomassen S; Mastenbroek TG; Swieringa F; Winckers K; Feijge MAH; Schrijver R; Cosemans JMEM; Maroney SA; Mast AE; Hackeng TM; Heemskerk JWM
Thromb Haemost; 2018 Mar; 118(3):502-513. PubMed ID: 29452445
[TBL] [Abstract][Full Text] [Related]
11. Heparanase procoagulant activity is elevated in women using oral contraceptives.
Matan M; Axelman E; Brenner B; Nadir Y
Hum Reprod; 2013 Sep; 28(9):2372-80. PubMed ID: 23800622
[TBL] [Abstract][Full Text] [Related]
12. Increased heparanase level and procoagulant activity in orthopedic surgery patients receiving prophylactic dose of enoxaparin.
Peled E; Rovitsky A; Axelman E; Norman D; Brenner B; Nadir Y
Thromb Res; 2012 Jul; 130(1):129-34. PubMed ID: 22154361
[TBL] [Abstract][Full Text] [Related]
13. Heparanase procoagulant activity.
Nadir Y; Brenner B
Thromb Res; 2012 Apr; 129 Suppl 1():S76-9. PubMed ID: 22682139
[TBL] [Abstract][Full Text] [Related]
14. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII.
Nadir Y; Brenner B; Fux L; Shafat I; Attias J; Vlodavsky I
Haematologica; 2010 Nov; 95(11):1927-34. PubMed ID: 20634491
[TBL] [Abstract][Full Text] [Related]
15. Heparanase procoagulant effects and inhibition by heparins.
Nadir Y; Brenner B
Thromb Res; 2010 Apr; 125 Suppl 2():S72-6. PubMed ID: 20434010
[TBL] [Abstract][Full Text] [Related]
16. Heparanase Level and Procoagulant Activity Are Increased in Thalassemia and Attenuated by Janus Kinase 2 Inhibition.
Ghoti H; Ackerman S; Rivella S; Casu C; Nadir Y
Am J Pathol; 2020 Oct; 190(10):2146-2154. PubMed ID: 32745462
[TBL] [Abstract][Full Text] [Related]
17. Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein.
Waters EK; Genga RM; Thomson HA; Kurz JC; Schaub RG; Scheiflinger F; McGinness KE
J Thromb Haemost; 2013 Jun; 11(6):1137-45. PubMed ID: 23528042
[TBL] [Abstract][Full Text] [Related]
18. Heparanase procoagulant activity, factor Xa, and plasminogen activator inhibitor 1 are increased in shift work female nurses.
Nadir Y; Saharov G; Hoffman R; Keren-Politansky A; Tzoran I; Brenner B; Shochat T
Ann Hematol; 2015 Jul; 94(7):1213-9. PubMed ID: 25743687
[TBL] [Abstract][Full Text] [Related]
19. Novel strategies of coagulation inhibition for reducing tumor growth and angiogenesis.
Nadir Y; Brenner B
Thromb Res; 2018 Apr; 164 Suppl 1():S153-S156. PubMed ID: 29703475
[TBL] [Abstract][Full Text] [Related]
20. Heparanase coagulation and cancer progression.
Nadir Y; Brenner B
Best Pract Res Clin Haematol; 2009 Mar; 22(1):85-92. PubMed ID: 19285275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
